Skip to main content

Table 6 Comparisons of trends in acquired non-susceptibility in Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae

From: Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study

Microbe Type of non-susceptibility Surveillance Area Trends in proportions of non-susceptibility (Time period)
E. coli Gentamicin non-susceptibility Levanger Hospital 0.5% (2002–05) 3.3% (2010–13)
Iceland 2.9% (2010) 4.1% (2013)
Norway 0.6% (2003) 7.7% (2014)
EU/EEA 5.2% (2002) 9.9% (2013)
Bulgaria 15.8% (2003) 32.1% (2013)
E. coli Resistance to 3rd generation cephalosporins Levanger Hospital 0 (2002–05) 1.7% (2010–13)
Norway 1.5% (2008) 5.8% (2014)
EU/EEA 2.0% (2002) 12.6% (2013)
Bulgaria 24.8% (2010) 39.6% (2013)
S. aureus MRSA Levanger Hospital 0 (2002–05) 1.0% (2010–13)
Norway 0.3% (2002) 0.8% (2014)
EU/EEA 25.6% (2007) 18.0% (2013)
Malta 52.0% (2007) 51.8% (2013)
Romania 39.1% (2010) 64.5% (2013)
S. pneumoniae PNSP Levanger Hospital 0 (2002–05) 3.0% (2010–13)
Netherlands 2.0% (2010) 1.1% (2013)
Norway 0.9% (2002) 5.5% (2014)
Cyprus 41.7% (2010) 40.0% (2013)
  1. MRSA, meticillin-resistant Staphylococcus aureus; PNSP, penicillin non-susceptible pneumococci
  2. Proportions of non-susceptibility from the current study (Levanger Hospital) are compared with data from Norway (the national surveillance system [8, 30], the European Union/the European Economic Area (EU/EEA), and with countries which have extraordinary low or high proportions of non-susceptibility [7, 24, 25]